Third, our study design lacked statistical power to support the significance of the association between the XPD Ly751Gln and XRCC1 Arg399Gln allelic variants and the OS in CRC patients treated with 5-FU-based chemotherapy (49% and 63%, respectively). This evidence concerns the gene XRCC1 and colorectal carcinoma.